CPX-POM

DRUG2 trials

Sponsors

CicloMed LLC

Conditions

Advanced Solid TumorBladder Cancer

Phase 1

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

CompletedNCT04608045

CicloMed LLCAdvanced Solid Tumor

Start: 2019-05-19End: 2023-04-30Updated: 2025-03-03

Phase 2

Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors

CompletedNCT04525131

CicloMed LLCBladder Cancer

Start: 2020-11-25End: 2023-06-30Updated: 2024-06-18

Related Papers

Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.

Journal of Clinical Oncology2022-06-01

Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

Cell Death and Disease2021-05-3113 citations